Advanced

EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.

Tennvall, Jan LU and Brans, Boudewijn (2007) In European Journal of Nuclear Medicine and Molecular Imaging 34(8). p.1324-1327
Abstract
Introduction P-32 phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom P-32 is the most optimal treatment option, an assertion supported by two large studies with long follow- up. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for P-32 phosphate therapy.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
nuclear medicine, guidelines, P-32 phosphate, polycythaemia vera, essential thrombocythaemia, radionuclide therapy
in
European Journal of Nuclear Medicine and Molecular Imaging
volume
34
issue
8
pages
1324 - 1327
publisher
Springer
external identifiers
  • wos:000248911800026
  • scopus:34548078380
ISSN
1619-7070
DOI
10.1007/s00259-007-0407-4
language
English
LU publication?
yes
id
1c0e6e91-fe31-4298-9032-2e41d1d35bae (old id 166130)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17396258&dopt=Abstract
date added to LUP
2007-07-24 11:09:33
date last changed
2017-06-04 03:39:32
@article{1c0e6e91-fe31-4298-9032-2e41d1d35bae,
  abstract     = {Introduction P-32 phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom P-32 is the most optimal treatment option, an assertion supported by two large studies with long follow- up. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for P-32 phosphate therapy.},
  author       = {Tennvall, Jan and Brans, Boudewijn},
  issn         = {1619-7070},
  keyword      = {nuclear medicine,guidelines,P-32 phosphate,polycythaemia vera,essential thrombocythaemia,radionuclide therapy},
  language     = {eng},
  number       = {8},
  pages        = {1324--1327},
  publisher    = {Springer},
  series       = {European Journal of Nuclear Medicine and Molecular Imaging},
  title        = {EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.},
  url          = {http://dx.doi.org/10.1007/s00259-007-0407-4},
  volume       = {34},
  year         = {2007},
}